Packages (Simulation)
Reagent Preparation
Image (I)
-
Results demonstration
Image (II)
-
Typical Standard Curve
Quality Guarantee
Instruction Manual
Certificate
Maybe you can also pay attention to our smart microplate reader
ELISA Kit for Anti-Folate Receptor 1, Adult Antibody (Anti-FOLR1)
FBP; FOLR; FR-alpha; MOv18; Adult folate-binding protein; KB cells FBP; Ovarian tumor-associated antigen MOv18
- Product No.AEF460Hu
- Organism SpeciesHomo sapiens (Human) Same name, Different species.
- Sample Typeserum, plasma and other biological fluids
- Test MethodIndirect ELISA
- Assay Length2h, 30min
- Detection Range3.12-200ng/mL
- SensitivityThe minimum detectable dose of this kit is typically less than 1.25ng/mL.
- DownloadInstruction Manual
- UOM 48T96T 96T*5 96T*10 96T*100
- FOB
US$ 630
US$ 900
US$ 4050
US$ 7650
US$ 63000
For more details, please contact local distributors!
Specificity
This assay has high sensitivity and excellent specificity for detection of Anti-Folate Receptor 1, Adult Antibody (Anti-FOLR1).
No significant cross-reactivity or interference between Anti-Folate Receptor 1, Adult Antibody (Anti-FOLR1) and analogues was observed.
Recovery
Matrices listed below were spiked with certain level of Anti-Folate Receptor 1, Adult Antibody (Anti-FOLR1) and the recovery rates were calculated by comparing the measured value to the expected amount of Anti-Folate Receptor 1, Adult Antibody (Anti-FOLR1) in samples.
| Matrix | Recovery range (%) | Average(%) |
| serum(n=5) | 99-105 | 102 |
| EDTA plasma(n=5) | 85-101 | 90 |
| heparin plasma(n=5) | 79-96 | 88 |
Precision
Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Anti-Folate Receptor 1, Adult Antibody (Anti-FOLR1) were tested 20 times on one plate, respectively.
Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Anti-Folate Receptor 1, Adult Antibody (Anti-FOLR1) were tested on 3 different plates, 8 replicates in each plate.
CV(%) = SD/meanX100
Intra-Assay: CV<10%
Inter-Assay: CV<12%
Linearity
The linearity of the kit was assayed by testing samples spiked with appropriate concentration of Anti-Folate Receptor 1, Adult Antibody (Anti-FOLR1) and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.
| Sample | 1:2 | 1:4 | 1:8 | 1:16 |
| serum(n=5) | 83-97% | 99-105% | 89-96% | 88-96% |
| EDTA plasma(n=5) | 84-103% | 92-101% | 96-104% | 90-102% |
| heparin plasma(n=5) | 81-89% | 96-105% | 81-99% | 79-92% |
Stability
The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition.
To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.
Reagents and materials provided
| Reagents | Quantity | Reagents | Quantity |
| Pre-coated, ready to use 96-well strip plate | 1 | Plate sealer for 96 wells | 4 |
| Standard | 2 | Standard Diluent | 1×20mL |
| Detection Reagent A | 1×120µL | Assay Diluent A | 1×12mL |
| TMB Substrate | 1×9mL | Stop Solution | 1×6mL |
| Wash Buffer (30 × concentrate) | 1×20mL | Instruction manual | 1 |
Assay procedure summary
1. Prepare all reagents, samples and standards;
2. Add 100µL standard or sample to each well. Incubate 1 hours at 37°C;
3. Aspirate and add 100µL prepared Detection Reagent A. Incubate 1 hour at 37°C;
4. Aspirate and wash 5 times;
5. Add 90µL Substrate Solution. Incubate 10-20 minutes at 37°C;
6. Add 50µL Stop Solution. Read at 450nm immediately.
GIVEAWAYS
INCREMENT SERVICES
| Magazine | Citations |
| Journal of maternal-fetal & neonatal medicine | Association of folic acid receptor α in maternal serum with neural tube defects Pubmed: 24094304 |
| Tumour Biol. | Quantitation of rare circulating tumor cells by folate receptor α ligand-targeted PCR in bladder transitional cell carcinoma and its potential diagnostic significance. Pubmed: 24771263 |